Edwards Lifesciences Corp on Tuesday said it stopped enrolling patients in a small study of its less-invasive mitral heart valve device due to the formation of blood clots associated with the procedure.
The company, which introduced a catheter-based approach to replacing diseased aortic heart valves in the U.S. market in 2011, is working to adapt the technique for the mitral valve.
12:23 Sterling volatile as market speculates on ‘hard Brexit’; investors await May's speech14
01:03 Sterling slides to three-month lows on 'hard Brexit' fears11
22:15 Sterling skids on Brexit anxiety; investors hope for Donald Trump clarity13
15:04 Hoping to save a 20 percent down payment? It's a big chunk of change14